The Latest Cardiac and Vascular News
– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 – –IPO and Nasdaq listing completed in February 2023 with total net proceeds of approximately $202.0 million, after deducting underwriting discounts, commissions and estimated offering costs – – […]
Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 16, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the […]
PHILADELPHIA, March 15, 2023 /PRNewswire/ — Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry, today announced Rod MacKenzie CMG, PhD. as their new Chairman of the Board of Directors. “I am excited to join the team at Clario,” said Dr. MacKenzie. “The company […]
Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST NEW YORK, March 14, 2023 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid […]
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing deals Potential U.S. market approval for Maxigesic® IV in H2 2023 Promising new product candidates driving innovation and on track for a planned acceleration towards a portfolio of 30 assets before 2025 Revenues of €3 million, net […]
Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial […]
DUBLIN–(BUSINESS WIRE)–FIRE1, today announced the close of a $25 million financing round led by new investors Andera Partners and Novo Holdings, with participation and ongoing support from existing investors Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates and Seventure Partners. The financing provides FIRE1 […]
Extends HeartBeam’s Reach with FDA-cleared Halo+™ Atrial Fibrillation Detection System and Physician-prescribed Integrated Patient Care Platform SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially […]
BURLINGTON, Mass., March 14, 2023 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, today announced that it has signed a definitive agreement to buy out its Thai distributor, Prompt Serve, for $688,000. In 2022 Prompt Serve purchased $950,000 of LeMaitre devices which […]
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing Windtree that it has […]
